Methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection - Scientific guideline

Table of contents

This document highlights key principles that should be considered by stakeholders with focus on use of genomic biomarkers in relation to patient selection and associated issues with trial methodology.

Keywords: Clinical trial designs, enriched design, genomic biomarkers (GBMS), hybrid design, predictive markers, pharmacogenomics, retrospective data analyses


How useful was this page?

Add your rating